Europa/Zentral-Asien. EMCDDA continues support for EU drug-related regional programme in Central Asia
Europa/Zentral-Asien. EMCDDA continues support for EU drug-related regional programme in Central Asia
The European drugs problem is increasingly linked to, and influenced by, global developments. The importance of identifying trends occurring in EU neighbouring countries and worldwide that could impact on the European drug situation is therefore underlined in the EMCDDA Strategy 2025. Among the agency’s work in the area of international cooperation is support for EU drug-related regional programmes. These include the Central Asian Drug Action Programme (CADAP), which is currently in its sixth phase (1). CADAP 6 reflects the EU’s long-term engagement with Central Asian partners to help further strengthen their national policies in drug demand reduction. (EMCDDA, Lissabon, 22.02.2018)
